Answers are grounded in this paper and cite their sources.
A series of 2-((5-amino-1,3,4-thiadiazol-2-yl)methyl)-6-aryl-2,3,4,5-tetrahydro-pyridazin-3-one (4a-e) was synthesized and evaluated for its in vitro antimycobacterial activity. All the synthesized compounds were structurally confirmed by using physicochemical and spectral analysis such as melting point, Rf value, elemental analysis, IR, NMR and mass spectra. In vitro antimycobacterial activity was screened by the microplate Alamar Blue Assay (MABA) method against Mycobacterium tuberculosis H37Rv strain. Derivatives with 4-ethyl phenyl substitution (4b) and chloro phenyl substitution (4e) at the p-position of pyridazinone nuclei showed good antimycobacterial activity with a MIC value of 6.25 μg/ml compared to other aryl substitutions such as 4-methoxy phenyl (4a), 4-methyl phenyl (4c) with a MIC value of 25 and 12.5 μg/ml. The results of in vitro antimycobacterial activity revealed that the synthesized compounds have potential antimycobacterial action and can be further optimized and developed as lead compounds.
No takes yet. Share an insight, caveat, or question.
Allahyani et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: